ABSTRACT
Early rapid screening diagnostic assay is essential for the identification, prevention, and evaluation of many contagious or refractory diseases. The optical density transducer created by platinum nanoparticles (PtNPs) (OD-CRISPR) is reported in the present research as a cheap and easy-to-execute CRISPR/Cas12a-based diagnostic platform. The OD-CRISPR uses PtNPs, with ultra-high peroxidase-mimicking activity, to increase the detection sensitivity, thereby enabling the reduction of detection time and cost. The OD-CRISPR can be utilized to identify nucleic acid or protein biomarkers within an incubation time of 30-40min in clinical specimens. In the case of taking severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) N gene as an instance, when compared to a quantitative reverse transcription-polymerase chain reaction (RT-qPCR), the OD-CRISPR test attains a sensitivity of 79.17% and a specificity of 100%. In terms of detecting prostate-specific antigen (PSA), aptamer-based OD-CRISPR assay achieves the least discoverable concentration of 0.01 ng mL-1. In general, the OD-CRISPR can detect nucleic acid and protein biomarkers, and is a potential strategy for early rapid screening diagnostic tools.
Subject(s)
COVID-19 , Metal Nanoparticles , Nucleic Acids , CRISPR-Cas Systems , Humans , Nucleic Acid Amplification Techniques , Platinum , SARS-CoV-2ABSTRACT
The control of contagious or refractory diseases requires early, rapid diagnostic assays that are simple, fast, and easy-to-use. Here, easy-to-implement CRISPR/Cas12a-based diagnostic platform through Raman transducer generated by Raman enhancement effect, term as SERS-CRISPR (S-CRISPR), are described. The S-CRISPR uses high-activity noble metallic nanoscopic materials to increase the sensitivity in the detection of nucleic acids, without amplification. This amplification-free platform, which can be performed within 30-40 min of incubation time, is then used for detection of SARS-CoV-2 derived nucleic acids in RNA extracts obtained from nasopharyngeal swab specimens (n = 112). Compared with the quantitative reverse transcription polymerase chain reaction (RT-qPCR), the sensitivity and specificity of S-CRISPR reaches 87.50% and 100%, respectively. In general, the S-CRISPR can rapidly identify the RNA of SARS-CoV-2 RNA without amplification and is a potential strategy for nucleic acid point of care test (POCT).
Subject(s)
CRISPR-Cas Systems/genetics , Nucleic Acid Amplification Techniques , SARS-CoV-2/genetics , SARS-CoV-2/isolation & purification , Spectrum Analysis, Raman , COVID-19/diagnosis , COVID-19/virology , Gene Expression Regulation, Fungal , Genes, Viral , Humans , RNA, Viral/analysis , Sensitivity and SpecificityABSTRACT
The ongoing Coronavirus Disease 2019 (COVID-19) broke out in China since December 2019, and rapidly spread worldwide. To contain the disease, unessential businesses had been shut down in several countries to a varying extent. Nowadays, the enterprises are resuming productions and businesses. While the resumption of production is crucial to social development, it elevates the risk of cluster-infections at the workplaces. Guangdong Second Provincial General Hospital therefore set up the Smart Safeguard System for COVID-19, aiming to provide rapid screening and consistent protection to assist the local enterprises with resumption. The system has received positive feedback as being helpful and practical. It has the potential to be widely used to prevent the cluster-infection of COVID-19 at workplaces during the pandemic.
Subject(s)
COVID-19 , Workplace , China/epidemiology , Humans , Pandemics , SARS-CoV-2ABSTRACT
The outbreak of SARS-CoV-2 rapidly spread across China and worldwide. Remdesivir had been proposed as a promising option for treating coronavirus disease 2019 (COVID-19). We provided a rapid review to critically assess the potential anti-coronavirus effect of remdesivir on COVID-19 and other coronaviruses based on the most up-to-date evidence. Even though remdesivir was proposed as a promising option for treating COVID-19 based on laboratory experiments and reports from compassionate use, its safety and effect in humans requires high-quality evidence from well-designed and adequately-powered clinical trials for further clarification.